Oregon State Drug Review

A monthly newsletter published by the College of Pharmacy on behalf of the OHA. Provides drug utilization reviews, drug and therapeutic guideline reviews, and cost-effective prescribing recommendations to Medicaid providers and pharmacies throughout Oregon. Each newsletter is offered in PDF format for viewing and printing.

You may elect to receive the newsletter monthly via email subscription through the OSUPHARMDI Listserv.

Volume 14 - 2024

Issue   Table of Contents
No. 3, March 2024   Asthma Relief Inhaler Drug Use Evaluation
No. 2, February 2024   Hepatitis C Care for Primary Care Providers
No. 1, January 2024   Updates for Insomnia: Evidence and Oregon Medicaid Policy

Volume 13 - 2023

Issue   Table of Contents
No. 9, December 2023   Opioid Reversal Agents
No. 8, November 2023   Prevention of Respiratory Syncytial Virus (RSV) Infection: New Products and Recommendations
No. 7, September 2023   An Update in Weight Loss Therapies - Including FDA Approved GLP-1 Receptor Agonists
No. 6, August 2023   2023 Global Initiative for Chronic Obstructive Lung Disease Report: Focus on Revised Recommendations for Inhaler Products
No. 5, July 2023   Update on the Use of SGLT-2 Inhibitors
No. 4, May 2023   Buprenorphine: Place in Therapy for Chronic Pain
No. 3, April 2023   COVID-19 Therapeutics Update: Where Are We Now? (Evidence updated through March 31, 2023)
No. 2, February 2023   Psychotropic Use in Youth Enrolled in the Oregon Health Plan and Youth in Foster Care with an Emphasis on Antipsychotic Prescription - *Correction to Previous Posting
No. 1, January 2023   Early and Periodic Screening, Diagnostic and Treatment (EPSDT) Benefit for Children and Adolescents

Volume 12 - 2022

Issue   Table of Contents
No. 9, November 2022   Hormone Replacement Therapy – A Focus on the Benefits and Risks of Estrogen
No. 8, October 2022   Pharmacological Prevention and Treatment of Monkeypox
No. 7, September 2022   COVID-19 Vaccine Bivalent Boosters
No. 6, August 2022   An Update in Lipid Lowering Therapies
No. 5, July 2022   Antimicrobial Stewardship
No. 4, May 2022   Population Trends in the Use of Migraine Preventative Treatments
No. 3, April 2022   Asthma Guidance Update with a Focus on Changes for Managing Patients with Mild Asthma
No. 2, March 2022   Updated 2021 Treatment Guidelines for Sexually Transmitted Infections
No. 1, January 2022   Second-Generation Antipsychotic Use in Children and Adolescents

Volume 11 - 2021

Issue   Table of Contents
No. 9, December 2021   A PEP Talk on PrEP-ing for HIV Prevention
No. 8, November 2021   Anti-SARS-CoV-2 Therapeutics can Effectively Treat, Prevent COVID-19 Infection
No. 7, September 2021   Updates in Heart Failure Therapy: New Drugs and Indications
No. 6, August 2021   Therapeutic Uses for Cannabinoids
No. 5, July 2021   Deprescribing Techniques to Minimize Safety Issues Associated with Inappropriate Polypharmacy
No. 4, May 2021   COVID-19 Vaccine Update
No. 3, March 2021   Bipolar Disorder: Resources for Primary Care Providers
No. 2, February 2021   Antidepressant Review
No. 1, January 2021   Coronavirus Disease-2019 Vaccine Update

Volume 10 - 2020

Issue   Table of Contents
No. 9, December 2020   2019-2020 Food and Drug Administration Drug Safety Communications Update
No. 8, November 2020   COVID-19 Viral Testing
No. 7, September 2020   Cardiovascular Outcomes Associated with Newer Therapy Classes for Type 2 Diabetes Mellitus
No. 6, August 2020   New Disease-Modifying Anti-Rheumatic Drugs for Management of Rheumatoid Arthritis
No. 5, July 2020   Shifts in the Treatment of Community Acquired Pneumonia
No. 4, May 2020   Optimizing the Use of NPH Insulin in Patients with Type 2 Diabetes Mellitus
No. 3, April 2020   Coronavirus Management: Evidence for Treatment and Drug Shortage Updates
No. 2, March 2020   Biosimilar Medications: Key Considerations for Providers
No. 1, January 2020   Evidence for Drugs that are Heavily Marketed

Volume 9 - 2019

Issue   Table of Contents
No. 9, December 2019   CGRP Antagonists in Migraine Prophylaxis
No. 8, November 2019   Update on Recent Guidance and Safety Alerts for Opioid Use in Non-cancer Pain
No. 7, September 2019   Pearls and Pitfalls of Clinical Practice Guidelines
No. 6, August 2019   Stimulant Use in Excessive Somnolence Disorders
No. 5, July 2019   Oregon Health Authority Mental Health Clinical Advisory Group (MHCAG) Recommendations for the Treatment of Schizophrenia
No. 4, May 2019   Update on Medications Used to Manage Opioid Use Disorder and Opioid Withdrawal
No. 3, March 2019   Non-statin Low-Density Lipoprotein Cholesterol (LDL-C) Lowering Therapy and Cardiovascular Outcomes
No. 2, February 2019   Benzodiazepine Safety and Tapering
No. 1, January 2019   2017-18 Year in Review: Important Safety Updates

Volume 8 - 2018

Issue   Table of Contents
No. 7, December 2018   Basal Insulin Update
No. 6, October 2018   Updates on Testosterone Therapy
No. 5, September 2018   Management Strategies for Patients with Prediabetes
No. 4, July 2018   Update on Treatment Options for Moderate to Severe Atopic Dermatitis
No. 3, May 2018   A Review of Implications of FDA Expedited Approval Pathways, Including the Breakthrough Therapy Designation
No. 2, March 2018   Second Generation Antipsychotic Use in Major Depressive Disorder
No. 1, January 2018   What's New with Biologic Agents for Inflammatory Disease?

Volume 7 - 2017

Issue   Table of Contents
No. 9, December 2017   Current Landscape of the Antidepressant Class: First Line Agents, Newer Agents, and Safety Risks
No. 8, November 2017   Marketing Claims of Newer Drugs and the Evidence
No. 7, August 2017   Oral Anticoagulant Update
No. 6, July 2017   Tramadol and Codeine Use In Pediatrics: A Review of Recent FDA Safety Alerts
No. 5, June 2017   New Biologics for Treatment of Moderate to Severe Psoriasis
No. 4, May 2017   Updates in the Management of Chronic Obstructive Pulmonary Disease
No. 3, April 2017   Management of Opioid Use Disorder
No. 2, March 2017   Non-Analgesics for Pain Management
No. 1, January 2017   Treatment of Gout

Volume 6 - 2016

Issue   Table of Contents
No. 8, December 2016   Guideline and Policy Updates for Use of Opioids for Non-Cancer Pain and Opioid Use Disorder
No. 7, October 2016   Endocrine Therapy for Breast Cancer
No. 6, August 2016   Vaccine Update 2016
No. 5, July 2016   Pharmacist Prescribed Contraceptives
No. 4, June 2016   Who Benefits from Calcium and Vitamin D Supplementation
No. 3, April 2016   Autism Spectrum Disorder Still Not Linked to the MMR Vaccine: A Review of the Studies since the 1998 Wakefield Study
No. 2, March 2016   Antidiabetic Treatments and Cardiovascular Implications
No. 1, February 2016   2015 in Review: Relevant Safety Updates and Ongoing Safety Concerns

Volume 5 - 2015

Issue   Table of Contents
No. 8, December 2015   Does Sacubitril/Valsartan Pose a Treatment Conundrum for Management of Heart Failure?
No. 7, November 2015   Obesity and Related Sequelae: Are Medications the Answer?
No. 6, October 2015   From Antidotes to Edoxaban: An Oral Anticoagulation Update
No. 5, August 2015   Is Long-Term Proton Pump Inhibitor Treatment for GERD Worth the Risk?
No. 4, June 2015   New Hypertension Guidelines: Do Blood Pressure Goals Need to Change with Age?
No. 3, May 2015   Treating UTIs with the Tried and True
No. 2, March 2015   Combating the Opioid Epidemic: Are Abuse-deterrent Formulations the Answer?
No. 1, February 2015   Evaluation of High Dose SSRI Initiation in Pediatrics and Young Adults

Volume 4 - 2014

Issue   Table of Contents
No. 8, November 2014   Guidance Update for Prophylaxis of Respiratory Syncytial Virus
No. 7, October 2014   What's New with Oral Anticoagulants?
No. 6, August 2014   New Hepatitis C Antiviral Therapies: How should they be used in clinical practice?
No. 5, June 2014   Update on New Therapies for Treating Major Depressive Disorder (MDD)
No. 4, May 2014   New Cholesterol Guidelines: A Significant Shift in Cholesterol Management
No. 3, April 2014   Second Generation Antipsychotics: Are these drugs effective in treating PTSD?
No. 2, March 2014   Evidence Based Review of Fish Oil: Going Beyond the Headlines
No. 1, January 2014   Strategies for Effective Monitoring and Management of Psychotropics in Children

Volume 3 - 2013

Issue   Table of Contents
No. 5, November 2013   Update on the New Oral Anticoagulants with a Focus on Apixaban
No. 4, October 2013   Updates and Comparisons of Type 2 Diabetes Treatment Guidelines
No. 3, August 2013   Managing Metabolic Side Effects in Children Receiving Antipsychotics
- Quick Reference Guides
No. 2, July 2013   Updates and Future Perspectives in the Management of Stable Chronic Obstructive Pulmonary Disease
No. 1, April 2013   Management of Gout in the Presence of Chronic Kidney Disease

Volume 2 - 2012

Issue   Table of Contents
No. 7, December 2012   The Future of Newer Obesity Medications
No. 6, September 2012   Do Spinosad or Ivermectin Have a Place in Head Lice Eradication?
No. 5, August 2012   Triple Therapy with the New Hepatitis C Protease Inhibitors: Challenges and Strategies
No. 4, June 2012   Can The Diabetic War Be Fought By Aggressive Blood Pressure Control?
No. 3, May 2012   Is Prasugrel or Ticagrelor a Better Choice Than the New Generic Clopidogrel?
No. 2, March 2012   Current Findings in the Off-Label Use of Atypical Antipsychotics
No. 1, January 2012   RSV Prophylaxis: Updates and Recommendations

Volume 1 - 2011

Issue   Table of Contents
No. 1, November 2011   Atypical Antipsychotic Drug Class Review


Past Issues of the DUR Board Newsletter:

Click Here





About the Oregon State Drug Review




We hope the Oregon State Drug Review newsletter is useful, thought provoking and interesting to our readers. Questions, concerns, comments, or suggestions are always welcome and should be addressed to the managing editor:

Kathy Sentena
OSU College of Pharmacy - Drug Use Research & Management @
OHA Division of Medical Assistance Programs
500 Summer Street NE, E35
Salem, OR 97301-1079
Phone: (503) 947-5220
Fax: 503-947-2596
sentenak @ ohsu.edu